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Abstract  
Objective: Meropenem is a parenteral carbapanem antibiotic which has a broad spectrum of activity 
against aerobes and aerobes. meropenem’s bactericidal activity is determined by the time during which 
meropenem concentration remains above the minimal inhibition concentration during the dosing 
interval. Thus, prolonged infusion is the optimal way to maximize the time dependant activity. However, 
studies to date have shown that carbapanems and in particular, meropenem-, are relatively unstable 
in solution. The aims of this study were therefore to: (1) establish the effects of temperature on the 
concentration of a generic brand reconstituted meropenem solution and (2) to determine whether 24 
hour continuous infusion is possible without concentrations dropping below the recommended 90%. 
Method: Preliminary examination was carried out by the means of nuclear magnetic resonance 
spectroscopy (NMR). meropenem was subsequently assayed using high performance liquid 
chromatography (HPLC). The method was developed and validated in compliance with International 
Council for Harmonisation (ICH) guidelines. meropenem’s stability was examined at two temperatures 
22oC and 33oC to mimic average and high temperature in hospital wards. Solutions were prepared 
aseptically at the clinically relevant concentration. 
Results: The results from the NMR study showed an increase in open ring methyl groups (δ=1.05 and 
1.25) peak intensity indicating that meropenem begins to degrade upon dissolution. Results obtained 
from quantitative HPLC confirm that meropenem concentrations dropped to 90% of initial 
concentration at 7.4 hours and 5.7 hours at 22oC and 33oC respectively. 
Conclusion: Although results obtained indicate that meropenem should not be continuously infused 
over 24 hours, it is possible that meropenem could be continuously infused for at least 7 hours if 
temperature doesn’t exceed 22oC and for 5 hours if temperature doesn’t exceed 33oC. 
Keywords: Meropenem; Stability; Continuous-Infusions; Temperature; IV Bags; Normal Saline  
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Abbreviations: MIC= Minimal Inhibition Concentration; CI= Continuous Infusion; II= Intermittent 
Infusion; YCD= Yellow Covered Document; NMR= Nuclear Magnetic Resonance; HPLC= High 
Performance Liquid Chromatography; IV= Intravenous; UV= Ultra-Violet; ICH= International Council for 
Harmonisation 
1 Introduction  
Antibiotic resistance is increasing to dangerously high levels worldwide threatening the effective 
prevention and treatment of an ever-increasing range of infections. The increasing occurrence of 
infection caused by multidrug-resistant, gram-negative bacterial pathogens, challenges clinicians to 
adopt new administration strategies with the intent of optimizing bactericidal activity of currently 
available beta-lactams [1-3].  
Meropenem is a parenteral carbapanem that is structurally related to B-lactam antibiotics such as 
penicillin and cephalosporin. It has an excellent bactericidal activity against a wide range of clinically 
significant gram-negative and gram-positive aerobic and anaerobic bacteria; thus known as a broad 
spectrum antibiotic [4- 7]. Meropenem is a time dependant antibiotic, hence bactericidal effects are 
closely correlated to the time at which concentrations remain above the minimal inhibition 
concentration (MIC) [8]. Periods at which concentrations are above the MIC (T>MIC) is a major 
parameter determining efficacy. When concentrations drop lower than the MIC (T<MIC) bacterial 
growth resumes immediately since meropenem has no significant post antibiotic effect [9-10].  
Meropenem is currently administered via intermittent bolus infusion (over ≈15-30 mins) which has 
numerous advantages including: better utilization of intravenous access, less concern about drug 
degradation over time and fewer compatibility concerns. This mode of administration however, results 
in concentrations falling below the MIC [11]. Although administration by continuous infusion maximises 
the pharmacodynamic properties, carbapanems, in particular meropenem are known to be quite 
unstable, hence a major parameter that needs to be studied [12]. The stability of meropenem should 
be maintained throughout the infusion time in order for the patient to receive abundant amounts of 
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active drug needed to achieve clinical cure while avoiding exposure to harmful degradation products 
[13].  
Various studies have demonstrated that continuous infusion of meropenem is beneficial in terms of 
efficacy based on pharmacokinetics and pharmacodynamics [14-18]. However to comply with the 
European and USA Pharmacopeia’s, beta lactam antibiotics should always contain at least 90-110% of 
the initial concentration [13].  
One of the major limitations of continuous infusion meropenem is that it would demand frequent drug 
preparation and administration due to its short stability [16-17]. This presents a challenge in practice 
as it requires pharmacy staff to produce multiple preparations and nursing staff to coordinate the 
multiple administrations throughout the day. Moreover, the problem is compounded in hospital wards 
where temperatures are not controlled therefore exposing the infusion to elevated temperatures that 
can compromise stability [14]. Therefore the aims of this study were to 1) establish the effects of 
temperature on the decomposition of reconstituted meropenem solutions and 2) to determine 
whether 24 hour continuous infusion is possible without concentrations dropping below the 
recommended 90% of the initial concentration.  
2 Methods  
Instrumentation: NMR spectroscopy was performed on 600mHz base frequency Bruker Advance lll Two-
channel FT-NMR spectrometer. Quantitative analysis was performed by the means of reverse-phase 
HPLC using an Agilent 1260 HPLC system with single wavelength UV detection and Chemstation 
Software. 
Materials: Meropenem reference standard, Methanol (HPLC grade), acetonitrile (HPLC grade), 
ammonium acetate, glacial acetic acid, and paracetamol were purchased from Sigma Aldrich. 0.9% 
saline was bought from Baxter and 100ml 0.9% saline infusion bags were obtained from St George’s 
hospital, London, UK. All of the above materials were used without further purification. Pharmaceutical 
dosages from meropenem infusion vials (1000mg) were prepared in a fume hood using an aseptic, non-
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touch technique. Generic brand, AstraZeneca, IV meropenem was reconstituted with 20ml water for 
injection and further diluted with 50ml of 0.9% saline.  
Preliminary investigation: Preliminary examination of meropenem was carried out by the means of 
Nuclear Magnetic Resonance (NMR) spectroscopy to provide an indication of how fast meropenem 
degraded and inform development of the High Performance Liquid Chromatography (HPLC) method. 
Meropenem solution at the clinically relevant concentration [(1000mg/70ml)*1000=14,285ppm] was 
placed in an NMR tube and instrument was programmed to periodically analyse throughout the day. 
The remainder of reconstituted solution was left at room temperature for two weeks and then analysed 
by HPLC to understand characteristics of meropenem degradation product/s.   
Method development: The aim was to develop a HPLC method capable of separating meropenem from 
its degradation products and measuring its concentration in infusion solutions, precisely and rapidly. 
Parameters investigated were mobile phase, column type, choice of internal standard, injection 
volume, flowrate, column temperature, linear range and detection wavelength.  
Method validation: The developed method was tested for linearity, range, precision, accuracy, 
specificity, sensitivity and robustness in compliance with ICH validation guidelines. The method was 
tested over the period of five days by running three replicates of a standard set of samples once a day 
for five days.  
Reconstituting 1g of meropenem powder for infusion with 20ml water for injection and mixing with 
50ml of saline (as in clinical practice) gives an infusion concentration of 14286ppm meropenem.  This 
solution will be diluted 1 in 50 for analysis, which reduces the amount of sample needed, reduces matrix 
effects and gives a nominal concentration of 286 ppm meropenem, in the usual analytical range for 
quantitative HPLC with UV detection. 
Analytical range was tested by injecting variable volumes (2, 4, 6, 8 10, 15 and 20µl) of a 1000ppm 
standard solution (equivalent to injecting 10µl of a set of standards, concentrations from 200-
2000ppm). Precision was considered at three levels; repeatability, intermediate precision and 
reproducibility. System and method precision were also considered.  
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Accuracy was determined by measurement of recovery and evaluated by using QC samples: (1) low 
(75ppm), (2) medium (250ppm) and, (3) high (450ppm).  
Specificity/selectivity was assessed by running diluent blanks. Diluent blanks included running a mobile 
phase, a saline and water for injection blank that were spiked with 250µl of the internal standard stock 
solution.  
Robustness parameters examined include changes in column temperature (±5oC), changes in flow rate 
(±0.2ml/min), changes in mobile phase pH (±0.2 units) and changes in the mobile phase composition 
(95:5: v/v; ammonium acetate: acetonitrile).  
Sample preparation: Two 1g meropenem pharmaceutical dose vials were emptied into a 250ml beaker 
and reconstituted with 40ml water for injection. 100ml 0.9% saline was added and the solution was 
stirred. Six 100ml 0.9% saline PVC IV bags were emptied completely, dried and injected using a 20ml 
syringe with same amount (20ml) of reconstituted bulk solution (14285ppm) and incubated at the 
relevant temperature 22oC and 33oC. The concentration of meropenem was measured every hour for 
21 hours after reconstitution and testing was performed in duplicate. The infusion solution was 
considered stable whilst the percentage of intact molecule remained above 90% (>90%).  
Physical Observation: Two responses were measured: physical compatibility and colour change. The 
solutions stored in IV bags were examined at every sampling interval for cloudiness, 
crystallisation/precipitation, colour change and signs of interactions.      
HPLC assay: The samples were diluted 50-fold with mobile phase (700μl) and paracetamol (250μl; 
concentration 1000ppm) was used as an internal standard (meropenem concentration=286ppm). The 
diluted samples were injected (injection volume 10μl) via an auto sampler onto a Synergi 4μ, POLAR-
RP-80R, 250x4.6mm column. The mobile phase was composed of 10mM ammonium acetate buffer 
adjusted to pH 5.4 with acetic acid and acetonitrile (90:10: vol/vol), isocratic elution at a flow rate of 
2.8ml/min. the UV detector wavelength was set to 290nm and the column temperature was set at 50+/-
1oC.  
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3 Results  
Method Validation  
The internal standard corrected calibration curve displayed good linearity over the concentration range 
of 0 to 500µl/ml. The representative linear equation was y=0.9943x-0.0566, with a correlation 
coefficient (R2) of 0.9998 (Figure.1). The regression line (R2=0.9996) in Figure.2 demonstrates linearity 
in the range 0- 2000ppm.  
Good system precision was obtained where intra-sample precision ranged between %RSD 0.01% and 
0.37%. Intra-day precision attained ranged between %RSD 0.25% and 1.90% and inter-day precision 
obtained ranged between %RSD 1.79% and 5.64%. 
The percentage error (%ERROR) determined from all standard QC samples was between 0.29 and 
0.68%, therefore %Recovery values obtained were at least 99.32%. For all blanks there was no 
significant response. meropenem reference standard solution was spiked with internal standard to 
ensure that peaks are well resolved.  
Increasing the column temperature decreased the pressure and retention time. Slight changes in 
mobile phase pH displayed no significant difference in peak area or peak shape.  The robustness study 
demonstrated that the method can optimally perform reproducibly when parameters change slightly. 
The limit of detection was 5.55ppm and the limit of quantitation was 16.82ppm.  
Preliminary Results  
The results of the preliminary NMR investigation are shown in Figure.3 below. The solution was 
analysed periodically by proton NMR with water suppression. The increase in peak intensity in the 
spectra, most prominently at chemical shifts of 1.05, 1.8, 2.5 and 2.6 ppm, suggests that meropenem 
begins to degrade upon dissolution. NMR was used as a qualitative method for characterisation rather 
than a quantitative technique as it would have been difficult to quantify due peak overlap. NMR 
8 
 
provided an estimation of how fast meropenem degraded, however, the instrument did not give an 
indication of concentration so further testing by HPLC was needed. 
Preliminary investigation by the means of HPLC was carried out to give an indication of how many 
degradants meropenem has and to obtain the retention time of both meropenem and the degradation 
product/s. Results displayed in Figure.4 shows the retention time of both meropenem and its 
degradation product/s. The spectra displays good resolution of meropenem and it degradant/s as no 
co-elution was observed and the compounds are not distinguished from one another.   
Physical Observation Results  
Upon preparation the solution was clear and colourless, but as the samples began to age the colour of 
the solution became tinged yellow. The older the sample the more distinct the colour change became. 
It was also observed that the change in colour was noticeable for solutions incubated at 33oC (7 hours) 
before solutions stored 22oC (12 hours).  
Quantitative Results  
Figure.5 shows the influence of time on meropenem concentrations at 22oC and 33oC, indicating the 
time at which meropenem concentration drops 10%. All data was drift-corrected and corrected with 
the internal standard. The slopes of the regression lines shown are statistically significant at the 99% 
level of confidence, indicating that meropenem concentrations decrease with time. 
Results show that meropenem maintained 90% intact molecule for 7.4 hours at 22oC and within 20 
hours, 71.2% of the initial concentration remained. meropenem maintained 90% intact molecule for 
5.7 hours at 33oC and within 20 hours, 61.4% of initial concentration was maintained.   
4 Discussion 
In recent years, stability studies have been given significant attention due to their importance in 
development and quality control of pharmaceutical products. meropenem has no significant post 
antibiotic effect as bactericidal activity is determined by the time at which the drug concentration 
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remains 4 or 5 times above the MIC. The interval between intermittent doses may result in meropenem 
concentrations falling below the MIC as high peak concentrations cannot enhance the bactericidal 
activity of meropenem [21].  
Determining meropenem stability could give an insight as to whether continuous infusions are feasible, 
thus, increasing patient response to therapy which can theoretically delay development of resistance. 
Numerous recent studies have assessed the clinical benefits of continuous/extended infusion 
compared to current intermittent dosing to optimize the bacterial activity of parenteral antibiotics for 
treating infections [12, 15, 22-26].  
Feher et al studied groups of patients receiving meropenem to determine whether the administration 
of meropenem via a 4h extended infusion leads to a more favourable clinical outcome. From this 
observational study it was concluded that treatment of febrile neutropenia was more successful with 
extended 4h infusions than 30 minute bolus infusion, with 68.4% and 40.9% of patients clinically cured 
respectively [P<0.001] [22]. Dulhunty et al observed the clinical and pharmacokinetic differences 
between continuous and intermittent dosing in critically ill patients with severe sepsis. Results obtained 
from this prospective controlled trial demonstrated that continuous infusion achieved higher antibiotic 
plasma concentration and also achieved higher rates of clinical cure (70% vs 43%; p=0.0037) [24].  
Continuously infusing meropenem will reduce the workload related to multiple administrations; 
however, the stability of meropenem is an important factor that needed consideration. Our findings 
confirmed that the stability of meropenem in solution was influenced by the storage temperature. Drug 
concentrations dropped to 90% of initial concentration after 7.4 hours at 22oC and 5.7 hours at 33oC. 
The visual colour change observed in meropenem solution is not reported in meropenem 
stability studies; however it is likely due to the degradation process and the formation of 
degradation product. Change in colour usually indicates that the beta-lactam ring has been 
hydrolysed. It is recommended that solutions that have changed colour should not be 
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administered to patients as changes in physical compatibility occur with loss of potency and an 
increase in toxicity. 
To our knowledge this is one of a few studies that examined the impact of elevated temperatures 
(experienced on hospital ward) on meropenem’s stability. Results obtained in this study suggest that in 
clinical settings with ambient temperatures below 33oC, extended infusion could be considered. Results 
from previous studies support our findings as they also suggested that the stability of meropenem 
reconstituted in solution is influenced by the storage temperature. At lower ambient temperatures 
meropenem is stable for a longer time than when stored at elevated temperatures [27]. Drug 
concentration is significantly reduced at high storage temperatures and should not be administered in 
tropical countries [14]. Smith et al looked at the stability of meropenem in different infusion devices at 
low temperatures and confirmed that meropenem was stable for 5 days at 5oC [26]. However  Kuti el 
al suggested that meropenem is stable for only ~4-6 hours at room temperature, and its 
pharmacokinetic properties, when administered by continuous infusion, are largely unknown [28].  
5 Conclusion 
Although results obtained determine that meropenem should not be continuously infused over 24 
hours it is suggested that patients can receive continuously infused meropenem for at least 7 hours if 
temperature doesn’t exceed 22oC and for 5 hours if temperature doesn’t exceed 33oC. 
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10 Figures  
Table.1 Showing the percentage of concentration remaining at each sampling interval for 22oC and 33oC 
Time (hrs) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
%R 22oC 100 105 115 99 91 93 90 90 87 87 84 81 82 82 82 81 76 76 78 78 78 78 
%R 33oC 100 106 107 99 91 91 85 85 82 84 79 74 77 77 77 73 68 66 70 68 67 67 
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Figure.1. Showing average seven concentration calibration (internal standard corrected) to assess linearity. 
Figure.2 Showing linearity in the range of 0-2000ppm 
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Figure.3 Preliminary NMR spectra of reconstituted meropenem 
Figure.4 Preliminary HPLC of aged meropenem sample to indicated degradation product/s retention time 
 
 
Figure.5 Showing the gradual decrease in meropenem concentration at both 22oC and 33oC 
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Figure.6 Showing meropenem %Recovery at all sampling intervals 
 
 
 
 
 
 
 
